R&D

Top 3 Sparks of Interest for Leading Vaccine Academics

Top 3 Sparks of Interest for Leading Vaccine Academics

Written by on July 24, 2014 in Featured on App, R&D with 0 Comments

Recently we undertook the research for the 15th annual World Vaccine Congress. As part of that research, we spoke to leading vaccine academics from the likes of University of Oxford and Erasmus MC to find out what they thought were the most interesting trends in industry at the moment. These were the top 3: 1. […]

Continue Reading

Researchers Create Vaccine for Dust-Mite Allergies

Researchers Create Vaccine for Dust-Mite Allergies

Written by on July 23, 2014 in Featured on App, R&D, Therapeutic Vaccines with 0 Comments

If you’re allergic to dust mites (and chances are you are) help may be on the way Researchers at the University of Iowa have developed a vaccine that can combat dust-mite allergies by changing the body’s immune response. In animal tests, the vaccine lowered lung inflammation by 83 percent, according to the paper published in […]

Continue Reading

Therapeutic

New Research Finds a Way to Predict Which HIV Patients Will Respond Better to Future Therapeutic Vaccine

New Research Finds a Way to Predict Which HIV Patients Will Respond Better to Future Therapeutic Vaccine

Written by on July 21, 2014 in Featured on App, R&D, Therapeutic Vaccines with 0 Comments

A new study suggests that HIV patients with a higher level of a particular biomarker may respond more favourably to an experimental immune activating vaccine Researchers at St George’s, University of London and Norwegian vaccine company Bionor believe the findings might lead to a customised vaccine for certain patients, which might permit them to come off […]

Continue Reading

The Herpes Zoster Vaccine: Effective Yet Underutilized

The Herpes Zoster Vaccine: Effective Yet Underutilized

Doctors say that despite the high effectiveness of the shingles vaccine, too many people are not getting it The Varicella Zoster Virus (VZV), the cause of chicken pox, is so common in children under the age of twelve that  90% of adults are immune to the condition because they’ve had it before. After infection from […]

Continue Reading

Prophylactic

GAVI Alliance Board Approves New 2016-2020 Framework

GAVI Alliance Board Approves New 2016-2020 Framework

Written by on July 24, 2014 in Featured on App, News, Prophylactic Vaccines with 0 Comments

The GAVI Alliance Board Have Approved a Framework That Will Support The Immunisation of an Additional 300 Million Children in Developing Countries The GAVI Alliance Board, a global health partnership committed to increasing access to immunisation in poor countries, has approved a new framework for 2016-2020 that will support the immunisation of an additional 300 million […]

Continue Reading

Extra Dose of Inactivated Polio Vaccine Provides Stronger Protection in Children

Extra Dose of Inactivated Polio Vaccine Provides Stronger Protection in Children

Written by on July 18, 2014 in Featured on App, News, Prophylactic Vaccines, R&D with 0 Comments

Amidst severe polio outbreaks in Asia, Africa and the Middle East, the WHO says that a “coordinated international response” is needed. Studies show that an extra dose of the of Inactivated Polio Vaccine (IPV) may be the solution. As the WHO has declared the spread of polio an “international public health emergency,” growing pressure has been […]

Continue Reading

Flu

New York City Stands up To Anti-Vaccine Parents

New York City Stands up To Anti-Vaccine Parents

Written by on June 26, 2014 in Flu, News, Regulation and Policy with 0 Comments

New York City judge rules that religious grounds are not enough to put your child in harm’s way The fight against unnecessary vaccine exemptions reached a milestone last week when a New York City judge ruled against three families who claimed that their right to free exercise of religion was violated when their un-vaccinated children […]

Continue Reading

DIY Spanish Flu: Critics up in arms as scientists recreate deadly 1918 virus

DIY Spanish Flu: Critics up in arms as scientists recreate deadly 1918 virus

Written by on June 13, 2014 in Flu, News with 1 Comment

Using a technique known as reverse genetics, a team from University of Wisconsin-Madison were able to build a virus 93% similar to the 1918 Spanish flu by utilizing 8 genes found in recent avian flu strains. The result was a flu virus more pathogenic than current avian flu strains, but less so than the Spanish […]

Continue Reading

Regulation & Policy

Lost Small Pox Vials and Anthrax Mishaps

Lost Small Pox Vials and Anthrax Mishaps

Written by on July 15, 2014 in News, Regulation and Policy, Supply Chain with 0 Comments

  Will small pox and anthrax biosafety concerns undermine vital research? Last week the US Centres for Disease Control and Prevention announced that 6 small pox vials had been discovered on the 1st of July during the clearing out of an old laboratory at the Nationality Institute of Health’s (NIH) Bethesda campus, Maryland. The six […]

Continue Reading

Vaccines & Adverse Events: A comprehensive guide

Vaccines & Adverse Events: A comprehensive guide

Written by on July 2, 2014 in Featured on App, News, Regulation and Policy with 0 Comments

Yet another report shows that vaccines are safe A meta-analysis, published today in Pediatrics, looked at 67 papers (reduced from 20,478 titles) on vaccine safety. The paper concluded that there is evidence to link some vaccines with serious adverse events, but that these adverse events are so extremely rare that, when weighed against the protective benefits […]

Continue Reading

Emerging Markets

World’s first Malaria Vaccine Submitted for Approval to EMA

World’s first Malaria Vaccine Submitted for Approval to EMA

Written by on July 24, 2014 in Emerging Markets with 0 Comments

GlaxoSmithKline submits the first malaria vaccine for approval by the European Medicines Agency and the World Health Organization The vaccine, named RTS,S, targets Plasmodium falciparum parasite. This parasite is most commonly found in sub-Saharan, where 90% of malaria related deaths occur. Children under 5 account for 77% of the deaths. The vaccine uses the AS01 adjuvant […]

Continue Reading

The Animal Medicine and Veterinary Vaccines Sector – a $22 billion market

The Animal Medicine and Veterinary Vaccines Sector – a $22 billion market

Written by on July 17, 2014 in Emerging Markets, News, Veterinary Vaccines with 0 Comments

  As highlighted by Zoetis , the largest global animal healthcare company and latest exhibitor partner to the Vaccine Congress Washington 2015, the animal medicines and veterinary vaccines sector is estimated to represent a global market of $22 billion within the approximate $92 – 102 billion animal health industry.   Additionally between 2011 and 2016, the […]

Continue Reading

Supply Chain

Ensuring Critical Vaccine Supply: Raw Materials Perspective

Ensuring Critical Vaccine Supply: Raw Materials Perspective

Written by on June 25, 2014 in Features & Downloads, Supply Chain with 0 Comments

Frank Appel, Senior Manager, Europe Vaccines Segments, Process Solutions, Merck Millipore joined us last year at the World Vaccine Congress Europe to present on ‘Ensuring Critical Vaccine Supply: Raw Materials Perspective.’ Download this presentation now to find out more about: Ensuring Safety: A real challenge & business risk The Reality of Upstream Contamination BioSafety Strategy […]

Continue Reading

4 Revolutionary Ways to Predict Pandemics

4 Revolutionary Ways to Predict Pandemics

Increasingly we are looking towards big data and analytics to help us with everything from how best to utilise your manufacturing capacity, to analysing potential candidates for emerging infectious diseases. But big data has been around for a number of years in the field of pandemic prediction. Here we have 4 of revolutionary methods that […]

Continue Reading

Strategy and Partnering

How to choose your perfect CRO partner

How to choose your perfect CRO partner

Deciding upon the correct CRO is a crucial element of each vaccine’s development for the likes of biotech’s and pharma, concerned with outsourcing their research. This eBook answers the all-important question of how to choose your perfect CRO partner by providing a checklist of the top 10 criteria that sponsors use for selecting CROs. Thereby […]

Continue Reading

Pfizer Vaccines: Behind the giant

Pfizer Vaccines: Behind the giant

Pfizer Vaccines business is one the biggest in the world, and plays host to the best selling vaccine in the world: Prevnar 13. And despite a very small product list, Prevnar’s dominance over the pneumococcal market allows them to bring in over $4 billion a year through Prevnar 13 alone. Pfizer Vaccines are also one of […]

Continue Reading

Other Recent Posts

GSK announces EU regulatory submission for malaria vaccine candidate RTS,S

July 24, 2014 GSK announced today that it has submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S. The submission will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union […]

Continue Reading

Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine For Upcoming 2014-2015 Season In United States

Largest U.S. influenza vaccine supplier, providing broad product portfolio, will distribute at least 65 million doses to help protect people across multiple age groups against the virus this season July 22, 2014 Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone® (Influenza Vaccine) for the 2014-2015 influenza (“the flu”) season […]

Continue Reading

Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects

Immunogenicity Data from Phase 1/2a Trial Highlighted at 39th Annual International Herpesvirus Workshop July 22, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody […]

Continue Reading

Top
Geolocation